Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
Postprint
DOI
PMC
 |
Open Access Green |
as soon as is submitted to ZB.
From basic science to diagnostics - History of a patent on a honeybee venom allergen.
Allergy 74, 385-387 (2019)
Hymenoptera venom can induce severe IgE-mediated systemic and even fatal allergic reactions. Fortunately, venom-specific immunotherapy (VIT) is one of the most effective disease-modifying curative treatments in the field of clinical allergology, but choosing the correct venom for VIT represents a crucial prerequisite for effective protection. In the past, therapeutic decisions based on specific IgE (sIgE) levels to whole venom extracts were not always straightforward. The presence of cross-reactive allergens and cross-reactive carbohydrate determinants (CCDs) in the extracts complicated the discrimination between cross-reactivity and true allergy to more than one venom. In the last years, the increasing knowledge of the composition of relevant venom allergens and the availability of recombinant CCD-free marker allergens resulted in the development of an advanced component-resolved diagnostics (CRD) of venom allergy. CRD has increased the sensitivity of sIgE detection and enabled the discrimination between primary sensitization and cross-reactivity, particularly in patients double-sensitized to honeybee and vespid venom.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Bee
ISSN (print) / ISBN
0105-4538
e-ISSN
1398-9995
Journal
Allergy
Quellenangaben
Volume: 74,
Issue: 2,
Pages: 385-387
Publisher
Wiley
Publishing Place
111 River St, Hoboken 07030-5774, Nj Usa
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute for Allergy Research (IAF)